Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
Looking Into Gossamer Bio’s Recent Short Interest
Gossamer Bio's (NASDAQ:GOSS) short percent of float has fallen 32.89% since its last report. The company recently reported that it has 14.41 million shares sold short, which is 17.59% of all regular shares that are available for trading.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers IsoPlexis (NASDAQ:ISO) stock moved upwards by 131.1% to $1.59 during Thursday’s regular session. Trading volume for IsoPlexis’s…
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Lowe’s To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Goldman Sachs raised Lowe’s Companies, Inc. (NYSE:LOW) price target from $241 to $246. . Goldman Sachs analyst Kate…
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $25 to $5.
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint.
Goldman Sachs Maintains Buy on Gossamer Bio, Lowers Price Target to $10
Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $22 to $10.